2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

humanised monoclonal antibody

" in MedChemExpress (MCE) Product Catalog:

18

Inhibitors & Agonists

21

Inhibitory Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P9980
    Belantamab

    GSK2857914

    		 TNF Receptor ADC Antibody Cancer
    Belantamab (GSK2857914) is a humanised IgG1 anti-BCMA (TNFRSF17) monoclonal antibody. Belantamab can be used in the synthesis of antibody-drug conjugate (ADC), Belantamab mafodotin .
    Belantamab
  • HY-P99201
    Zilovertamab

    UC-961; Cirmtuzumab

    		 ROR Cancer
    Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling .
    Zilovertamab
  • HY-P99028
    Ibalizumab

    TMB-355; TNX-355

    		 HIV Infection
    Ibalizumab (TMB-355) is a humanised IgG4 monoclonal antibody that prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research .
    Ibalizumab
  • HY-145645
    Paridiprubart

    NI-0101

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Paridiprubart (NI-0101) is a humanised anti-TLR4 monoclonal antibody. Paridiprubart has the potential for the research of rheumatoid arthritis .
    Paridiprubart
  • HY-P99855
    Divozilimab

    BCD-132

    		 CD20 Inflammation/Immunology
    Divozilimab (BCD-132) is a humanised monoclonal antibody against CD20 (CD20). Divozilimab can be used for multiple sclerosis research .
    Divozilimab
  • HY-P990095
    Vonsetamig

    		CD3 TNF Receptor Cancer
    Vonsetamig is a humanised immunoglobulin G4-kappa, anti-TNFRSF17 and CD3E monoclonal antibody. Vonsetamig is an antineoplastic .
    Vonsetamig
  • HY-P99555
    Tomaralimab

    OPN-305

    		 Toll-like Receptor (TLR) Inflammation/Immunology
    Tomaralimab (OPN-305) is a humanised anti-TLR2 IgG4 monoclonal antibody. Tomaralimab has the potential for the research of Myelodysplastic Syndromes (MDS) .
    Tomaralimab
  • HY-P99758
    Nofazinlimab

    CS1003

    		 PD-1/PD-L1 Cancer
    Nofazinlimab (CS1003) is a humanised IgG4 anti-PD-1 monoclonal antibody. Nofazinlimab can be used for unresectable hepatocellular carcinoma (uHCC) research .
    Nofazinlimab
  • HY-P99177
    Enibarcimab

    		SARS-CoV Infection Cardiovascular Disease
    Enibarcimab is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody, could be used for acute heart failure, COVID-19 infections and septic shock research .
    Enibarcimab
  • HY-P99380
    Zanidatamab

    ZW 25

    		 EGFR Cancer
    Zanidatamab (ZW25) is a humanised, bispecific monoclonal antibody targeting 2 distinct HER2 epitopes (ECD2 and ECD4). Zanidatamab has anti-tumour activity .
    Zanidatamab
  • HY-P99183
    Abituzumab

    EMD 525797; DI17E6

    		 Integrin Cancer
    Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer .
    Abituzumab
  • HY-P99648
    Gosuranemab

    BMS-986168; IPN007; BIIB092

    		 Tau Protein Neurological Disease
    Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD) .
    Gosuranemab
  • HY-P99216
    Ponezumab

    PF-04360365; RN 1219

    		 EGFR Neurological Disease
    Ponezumab (PF-04360365) is a humanised anti-amyloid IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves performance in mice in various models of learning and memory. Ponezumab can be used in study of Alzheimer's disease .
    Ponezumab
  • HY-P99298
    Lampalizumab

    RG 7417; TNX 234; Anti-CFD Recombinant antibody

    		 Complement System Inflammation/Immunology
    Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research .
    Lampalizumab
  • HY-P99280
    Bimekizumab

    Anti-Human IL17A/IL-17F Recombinant antibody

    		 Interleukin Related Inflammation/Immunology
    Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralises IL-17A and IL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation .
    Bimekizumab
  • HY-P990093
    Stapokibart

    CM310

    		 Interleukin Related Inflammation/Immunology
    Stapokibart (CM310) is a humanised monoclonal antibody targeting IL-4Rα and efficiently blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit IL-4Rα. Stapokibart has the capacity to interact with IL-4Rα in humans, cynomolgus monkeys, and rats .
    Stapokibart
  • HY-P99248
    Risankizumab

    Risankizumab rzaa; BI 655066

    		 Interleukin Related Inflammation/Immunology
    Risankizumab (BI 655066) is a humanised IgG monoclonal antibody, targeting IL-23 p19 subunit (Kd <10 pM) and inhibiting IL-17 production induced by human IL-23 in mouse splenocytes (IC50 = 2 pM). Risankizumab can be used to research immunological and inflammatory disorders such as psoriasis vulgaris, psoriatic arthritis, generalized pustular psoriasis and erythrodermic psoriasis .
    Risankizumab
  • HY-P99378
    Neihulizumab

    ALTB-168; Anti-PSGL1/CD162 Reference antibody (neihulizumab)

    		 Apoptosis Inflammation/Immunology
    Neihulizumab (ALTB-168) is an immune checkpoint agonistic antibody that binds to human CD162 (PSGL-1), leading to downregulation of activated T-cells. Neihulizumab can be uesd for steroid-refractory acute graft-versus-host-disease (SR-aGVHD), psoriasis, psoriatic arthritis and ulcerative colitis research .
    Neihulizumab

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: